2023 World Conference on Lung Cancer (Posters)-EP12.01. Erlotinib and Ramucirumab Combination Therapy for Patients Previously Treated with EGFR-TKI: A Retrospective Observational Study

EP12.01. Erlotinib and Ramucirumab Combination Therapy for Patients Previously Treated with EGFR-TKI: A Retrospective Observational Study - PDF(Slides)

Back to course

Pdf Summary

This study aimed to evaluate the efficacy of combination therapy with erlotinib and ramucirumab in patients previously treated with EGFR-TKIs for EGFR mutation-positive lung cancer. A total of 10 patients who received the combination therapy were included in the analysis, and 8 of them had prior EGFR-TKI treatment. The median age of the patients was 69 years, and the majority were female. The median ECOG performance status was 1. The combination therapy showed a response rate of 25% and disease control rate of 75%. The median progression-free survival was 214 days. The study also discussed the role of VEGF signaling and TP53 mutations in EGFR mutation-positive lung cancer and the potential of combination therapy with EGFR-TKIs and VEGF inhibitors.<br /><br />The combination of erlotinib and ramucirumab has been shown to be effective as a first-line therapy for EGFR mutation-positive lung cancer. However, its efficacy in patients previously treated with EGFR-TKIs was unknown. This study provides evidence that the combination therapy can still be effective in these patients, even as a late-line therapy. The study suggests that inhibition of both the EGFR and VEGF pathways can improve antitumor efficacy and overcome resistance to EGFR inhibition. The study also highlights the potential importance of TP53 mutations in EGFR mutation-positive lung cancer and their impact on treatment outcomes.<br /><br />In conclusion, this retrospective observational study suggests that combination therapy with erlotinib and ramucirumab can be effective in patients previously treated with EGFR-TKIs for EGFR mutation-positive lung cancer. Further research is needed to validate these findings and explore the potential benefits of this combination therapy in larger patient populations.

Asset Subtitle

Tomoki Tamura

Meta Tag

Speaker Tomoki Tamura

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

combination therapy

erlotinib

ramucirumab

EGFR-TKIs

EGFR mutation-positive lung cancer

VEGF signaling

TP53 mutations

response rate

disease control rate

progression-free survival